WHO ICTRP trial
AMG 386 1st Ovarian cancer Global Phase 3 clinical trial
JPRN-jRCT2080221781 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221781 |
|---|---|
| Public title | AMG 386 1st Ovarian cancer Global Phase 3 clinical trial |
| Scientific title | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers |
| Primary sponsor | Takeda Pharmaceutical Company Limited |
| Secondary sponsors | Amgen Inc., U.S.A. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | First-line treatment of subjects with International Federation of Gynecology and Obstetrics (FIGO) Stage III-IV epithelial ovarian, primary peritoneal or fallopian tube cancers |
| Interventions | investigational material(s) Generic name etc : AMG 386 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous control material(s) Generic… |
| Registration date | Apr 26, 2012 |
| Target size | 2000 |
| Secondary IDs | JapicCTI-121823 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: